Biosimilars, drug shortages are on the Belgian antitrust radar
By Anna Ferrari ( May 23, 2025, 12:58 GMT | Insight) -- The Belgian competition authority will focus on pharma companies in cases where their practices might hamper the availability of essential medicines for Belgian patients, as well as when they might unlawfully coordinate drug placement, said a senior Belgian enforcer. It is also working on a clarification for combination therapies. Enforcement in the pharma sector is a priority for the Belgian competition authority, according to a senior Belgian enforcer....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.